Switching From Preserved to Preserved-free Treatments for Glaucoma.

Inclusion Criteria: * The patient is suffering from ocular hypertension, POAG, PEX, NTG. Glaucoma definition is based on the European Glaucoma Society Guidelines. * The patient is newly-diagnosed * No fluorescein staining at baseline and no observable signs of ocular surface disease * No treatment with topical BAK-containing products for at least 6 months * Treatment of naïve patients Exclusion Criteria: * Unwilling to sign informed consent * Not at least 18 years old * Ocular condition that are of safety concern and that can interfere with the study results * Closed/barely open anterior chamber angles or history of acute angle closure. * Ocular surgery or argon laser trabeculoplasty within the last year. Ocular inflammation/infection occurring within three months prior to pre-trial visit. * Presence of the following ocular conditions: KCS, moderate-severe blepharitis, Rosacea, Sjogren syndrome, pterygium, contact lens users. * Use of concomitant topical ocular medication that can interfere with study medication * Hypersensitivity to benzalkonium chloride or to any other component of the trial drug solutions. * Any corneal pathology * Diabetes at any stage * Other abnormal condition or symptom preventing the patient from entering the trial, according to the Investigator's judgement. * Refractive surgery patients * Women who are pregnant, are of childbearing potential and are not using adequate contraception or are nursing. * Inability to adhere to treatment/visit plan. * Have participated in any other clinical trial (i.e., requiring informed consent) within one to three month prior to pre-trial visit (depending on ethics committee decisions).